Genicular artEry embolizatioN in patiEnts with oSteoarthrItiS

of the knee (GENESIS) using permanent microspheres: interim

analysis by Little, M. W. et al.
Genicular artEry embolizatioN in patiEnts 
with oSteoarthrItiS of the knee (GENESIS)  




Creative Commons: Attribution 4.0 (CC-BY) 
Open Access 
Little, M. W., Gibson, M., Briggs, J., Speirs, A., Yoong, P., 
Ariyanayagam, T., Davies, N., Tayton, E., Tavares, S., 
MacGill, S., McClaren, C. and Harrison, R. ORCID: 
https://orcid.org/0000-0003-3674-9622 (2021) Genicular artEry 
embolizatioN in patiEnts with oSteoarthrItiS of the knee 
(GENESIS) using permanent microspheres: interim analysis. 
Cardiovascular and Interventional Radiology. ISSN 0174-1551 
doi: https://doi.org/10.1007/s00270-020-02764-3 Available at 
http://centaur.reading.ac.uk/95642/ 
It is advisable to refer to the publisher’s version if you intend to cite from the 
work.  See Guidance on citing .
To link to this article DOI: http://dx.doi.org/10.1007/s00270-020-02764-3 
Publisher: Springer 
All outputs in CentAUR are protected by Intellectual Property Rights law, 
including copyright law. Copyright and IPR is retained by the creators or other 
copyright holders. Terms and conditions for use of this material are defined in 
the End User Agreement . 
www.reading.ac.uk/centaur 
CentAUR 
Central Archive at the University of Reading 
Reading’s research outputs online
CLINICAL INVESTIGATION EMBOLISATION (ARTERIAL)
Genicular artEry embolizatioN in patiEnts with oSteoarthrItiS
of the Knee (GENESIS) Using Permanent Microspheres: Interim
Analysis
M. W. Little1,3 • M. Gibson1 • J. Briggs1 • A. Speirs1 • P. Yoong1 •
T. Ariyanayagam1 • N. Davies2 • E. Tayton2 • S. Tavares2 • S. MacGill1 •
C. McLaren1 • R. Harrison3
Received: 22 June 2020 / Accepted: 28 December 2020
 The Author(s) 2021
Abstract
Purpose Planned interim analysis of GENESIS; a
prospective pilot study investigating the role of genicular
artery embolization (GAE) in patients with mild to mod-
erate osteoarthritis of the knee using permanent
microspheres.
Methods Thirty-eight patients, median age = 60 (45–83),
attended for GAE using 100–300 lm permanent micro-
spheres. All patients had mild to moderate knee OA,
resistant to conservative treatments over 6 months. Knee
MRI was performed at baseline, and 12 months, enabling
semi-quantitative analysis using Whole-Organ Magnetic
Resonance Imaging Score (WORMS). Knee Injury and
Osteoarthritis Outcome Score (KOOS) and visual analogue
scale (VAS) (0–100 mm) were completed at baseline,
6 weeks, 3 months (n = 32), and 1-year (n = 16). Adverse
events were recorded prospectively.
Results Technical success of accessing and embolizing the
target genicular arteries was 84%. Six patients were not
embolized: four due to a presumed risk of non-target
embolization, and two due to a lack of hyperaemic target.
Mean VAS improved from 60 (SD = 20, 95% CI 53–66) at
baseline to 36 (SD = 24, 95% CI 28–44) at 3 months
(p\ 0.001) and 45 (SD = 30, 95% CI 30–60) at 1-year
(p\ 0.05). All KOOS subscales showed a significant
improvement at 6-weeks, 3-months, and 1-year follow-up,
except function in daily living, which reached borderline
significance (p = 0.06) at 1-year. Four patients experienced
mild self-limiting skin discoloration over the embolized
territory. One patient experienced a small self-limiting
groin haematoma. WORMS scores at 1-year follow-up
showed significant improvement in synovitis (p\ 0.05).
There were no cases of osteonecrosis.
Conclusion GAE using permanent microspheres in
patients with mild to moderate knee OA is safe, with
potential efficacy at early follow-up.
Keywords Osteoarthritis  Knee  Embolization 
Genicular
Introduction
Osteoarthritis (OA) of the knee joint is the most common
articular disease of the developed world, and a leading
cause of chronic disability, and economic burden [1].
Treatment options include analgesia, physiotherapy, intra-
articular steroid, platelet-rich plasma (PRP), or hyaluronic
injections, education programs, weight loss, and anti-in-
flammatory preparations. Joint replacement surgery is
generally reserved for those with severe joint disease, pain,
and functional limitation [2]. Despite this, expectations of
surgery are not met in up to 30% of patients undergoing
total knee replacement (TKR) [3]. Mild to moderate knee
OA, not yet severe enough to warrant joint replacement,
and resistant to nonsurgical options, represents a specific
management challenge that justifies research into the area.
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Like many multi-factorial conditions, there remains to
be a grand unified theory to explain the pathogenesis of
OA. Work has elucidated the role of angiogenesis in the
pathophysiology of knee OA. Mapp et al. found that
angiogenesis is increased in the synovium, osteophytes,
and menisci [4]. New abnormal blood vessel growth results
from macrophage activation within the synovium that is
driven by inflammation. Pro-angiogenic factors such as
vascular endothelial growth factor (VEGF), b-nerve
growth factor, and neuropeptides have been identified as
propagating neo-angiogenesis, and disrupting the osteo-
chondral junction [5–7]. As sensory nerves grow along new
blood vessels in osteoarthritic joints, they eventually pen-
etrate non-calcified articular cartilage, osteophytes, and the
inner regions of the menisci. It is hypothesized that
angiogenesis contributes to structural damage and pain in
OA, and thus may therefore provide a potential
embolization target. Okuno et al. were the first group to
describe their experience of genicular artery embolization
(GAE) in patients with knee OA [8]. Since then, a small
number of studies have reported on the role of GAE in the
treatment of knee OA [8–12]. The Genicular artEry
embolizatioN in patiEnts with oSteoarthrItiS of the knee
(GENESIS) study investigates the safety and feasibility of
performing GAE in patients with mild to moderate knee
OA using permanent microspheres.
Materials and Methods
GENESIS is a prospective single-centre pilot study with
full ethical approval and is adopted onto the National
Institute for Health Research (NIHR) portfolio (IRAS:
237676, CPMS: 37741). Planned interim analysis was
performed to assess safety, and feasibility of GAE. Patients
presenting to the department of orthopaedics with knee OA
were considered for the study. Inclusion criteria included
age 45 years or older, mild to moderate knee OA as
determined on X-ray as Kellgren–Lawrence (KL) grade
1–3, and knee pain present for at least 6 months, resistant
to conservative treatment (physiotherapy/analgesia/exer-
cise/weight loss/intra-articular injections). Patients were
excluded if they had rheumatoid or infectious arthritis,
severe knee OA (KL-grade 4), renal impairment
(eGFR\ 45), a bleeding diathesis, irreversible coagu-
lopathy, or previous knee arthroplasty. All patients were
reviewed in clinic by a consultant orthopaedic surgeon and
deemed suitable for inclusion. They were then assessed by
the interventional radiology research team and consented
for inclusion into the study.
Patients’ symptoms were evaluated using the Knee
Injury and Osteoarthritis Outcome Score (KOOS) ques-
tionnaire, and a visual analogue scale (VAS) (0–100 mm)
[13, 14]. These outcome measures were repeated at
6-week, 3-month (n = 32), and 1-year (n = 16) post-GAE.
The KOOS questionnaire is a validated tool consisting of
five subscales (pain, other symptoms, function in daily
living, function in sport and recreation, and knee related
quality of life) able to quantify changes in knee OA post-
intervention; a normalized score (100 indicating no
symptoms and 0 indicating extreme symptoms) is calcu-
lated for each subscale. Patient’s knee-specific analgesia
use was recorded at baseline, 6-weeks, 3-months, and 1-
year follow-up. Paracetamol, non-steroidal anti-inflamma-
tory drugs (NSAIDs), and opiates were recorded. Finally,
patient satisfaction questionnaires were designed to ascer-
tain patient-reported outcome measures (PROM) on the
GAE procedure. The questionnaires were completed by the
patients prior to discharge on the day of the GAE
procedure.
Prior to GAE, participants underwent contrast-enhanced
MRI of the knee to allow non-invasive assessment of
synovial hypervascularity as previously described [15, 16].
Images were acquired on a Philips Ingenia 3T MRI scan-
ner. Proton density fat-saturation (PDFS), sagittal (Slice-
thickness (ST) 2.5, TR 4177 ms, TE 30 ms, field of view
(FOV) 144, matrix 360 9 286), axial (ST 3, TR 4589, TE
30, FOV 144, matrix 360 9 275), and coronal sequences
(ST 2.5, TR 4848, TE 30, FOV 160, matrix 516 9 366)
were acquired. In addition, contrast-enhanced imaging was
acquired using axial T1-FS (ST 3, TR 578, TE 20, FOV
144, matrix 344 9 276), and sagittal T1-FS (ST 2.5, TR
697, TE 20, FOV 144, matrix 344 9 276) sequences. MRI
of the knee was repeated at 12-month follow-up. Whole-
Organ Magnetic Resonance Imaging Score (WORMS) was
used to standardize imaging assessment pre and post-in-
tervention as previously described [17]. Images were
independently reviewed by two musculoskeletal radiolo-
gists with 11 and 6 years of experience. Both radiologists
had prior training and experience of WORMS. They were
blind to patient characteristics and outcome measures
(KOOS and VAS).
Genicular Artery Embolization for Knee OA
All GAE procedures were carried out by two consultant
interventional radiologists with 6 and 25 years’ experience.
Ultrasound-guided anterograde access of the common
femoral artery was performed, with insertion of a 4F vas-
cular sheath (Cordis Medical, USA). A hydrophilic
guidewire (Terumo, Japan) and Cobra Performa catheter
(Merit Medical, USA) were used to gain access to the distal
superficial femoral artery, from where angiography was
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carried out using 300 mg/ml iodinated contrast (Iomeron,
Bracco, Italy) to visualize the genicular arterial anatomy
(Fig. 1). A hyperaemic blush signified the pathological
target as previously described [9, 10, 16]. Using a Fathom
14 guidewire (Boston Scientific, USA) for vessel selection,
a straight-tip microcatheter (2.9–2.0F Pursue, Merit Med-
ical, USA) was introduced through the base catheter into
the genicular arteries supplying the pathological synovium
(Fig. 2). Glycerol trinitrite (GTN) was injected through the
microcatheter to optimize anterograde flow into the
hypervascular synovium. A sports ice pack was placed on
the skin surface of the knee corresponding to the area to be
embolized. The hypothesis for the use of an icepack is that
the reduced temperature will result in temporary vasocon-
striction, minimizing non-target embolization to cutaneous
arterial branches. The ice pack was left in situ for 15-min.
Cone-beam-CT (Philips Allura FD20) was performed,
injecting 6 ml of 100% iodinated contrast (Iomeron,
Bracco, Italy) at 0.3 ml/s with a 6 s delay. This enabled
confirmation of the hyperaemic target and identified con-
trast enhancement of adjacent skin, muscle, or bone, min-
imizing non-target embolization. Once a safe and effective
microcatheter position was confirmed, the target vessels
were embolized with 100–300 lm Embosphere particles
(Merit Medical, USA) dilute in 20 ml (300 mg/ml) iodi-
nated contrast (Iomeron, Bracco, Italy). Embolization was
performed cautiously injecting 0.1–0.3 ml of embolic at a
time using a 3-ml syringe. The aim of GAE in the
Fig. 1 Non-selective angiography from the distal superficial femoral
artery, revealing the genicular arterial anatomy. The medial joint
compartment is supplied by the descending (red), superior (light
blue), and inferior (purple) medial genicular arteries. The lateral joint
compartment is supplied by the superior (dark blue) and inferior
(green) genicular arteries, as well as the anterior tibial recurrent
(yellow) genicular artery. The patellofemoral joint takes arterial
supply from all six genicular arteries
Fig. 2 A Superior medial genicular artery is selected revealing
hyperaemic synovium within the medial knee compartment in a
patient with grade 2 KL knee OA. B Area was embolized with 2 ml
100–300 lm Embosphere particles diluted in 20 ml contrast, to prune
the abnormal vascularity revealing the post-embolization appearance
Fig. 3 There is a rich anastomotic network between the genicular
arteries. Contrast injected from the musculo-articular branch of the
descending genicular artery reveals hyperaemic synovium within the
medial knee compartment, and retrograde filling of the superior
medical genicular, and popliteal arteries
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osteoarthritic knee is to ‘‘prune’’ the abnormal vessels and
maintain the larger native distal genicular branches
(Fig. 2). The mean fluoroscopy duration was 14.29 min
(SD = 9.58), and mean cumulative air kerma was 96 mGy
(SD = 75). Patients recovered in the interventional radiol-
ogy recovery unit for 4-h and were discharged home the
same day. In order to minimize bias, data collection was
completed by the radiology research nursing team, rather
than the interventional radiologists performing the proce-
dure. Technical success was defined as selective catheter-
ization and embolization of the target genicular arteries.
The minimum clinically important difference (MCID) for
GAE has not been defined. Based on work by Roos, a
MCID of 10 was used for KOOS scores, which is the upper
limit of the recommended range [18].
Statistical Analysis
The KOOS scores were summarized using descriptive
statistics for each visit. Boxplots were also produced by
visit. Adjusted means and differences from baseline
(n = 32) along with 95% confidence intervals were
derived. p values are presented for the differences between
baseline and 6 weeks, 3 months (n = 32), and 1-year
(n = 16). All applicable tests were two tailed using a 5%
alpha significance level. WORMS inter-observer agree-
ment was assessed by calculating intraclass correlation
coefficients (ICC). The comparison of ratings was com-
pleted using a two-way mixed design, evaluating consis-
tency, with 95% confidence intervals. Analyses were
performed using MiniTab v.19.2020.01, Microsoft Excel v.
14.0.7015.1000, and SPSS Statistics v23.0.
Results
Thirty-eight patients (median age = 60, range = 45–83)
attended for GAE between June 2018 and January 2020
(Table 1). Eighteen patients with KL-grade 3, 17 with KL-
grade 2, and 3 with KL-grade 1 were included. Despite
cannulating all target genicular arteries, technical success
was 84%, as six patients were not embolized: one due to
significant cutaneous supply, and three because of anasto-
motic communication between the selected target genicular
artery, and the popliteal artery, which might have resulted
in distal non-target embolization (Fig. 3). Two further
patients were not embolized due to a lack of hyperaemic
target.
The mean follow-up was 8 months (3–12 months).
Mean VAS at baseline was 60 (SD = 20, 95% CI 53–66),
reducing to 32 (SD = 25, 95% CI 24–42) at 6 weeks
(p\ 0.001), 36 (SD = 24, 95% CI 28–44) at 3 months
(p\ 0.001), and 45 (SD = 30, 95% CI 30–60) at
12 months (p\ 0.05) (Fig. 4). KOOS subscales showed a
statistically significant improvement from baseline to 6
weeks (p\ 0.001), 3 months (p\ 0.001), and 1-year
(\ 0.05) in all outcome measures except function in daily
living, which revealed borderline significance at 12 months
(p = 0.06) (Table 2, Fig. 4).
Interclass correlations indicated a good-to-excellent
level of consistency between the two observers across total
WORMS assessments [19]. ICCs were calculated between
both, pre-treatment WORMS ratings (Average Measure-
ment ICC = 0.952, 95% CI = 0.857–0.984, F(14,
14) = 20.89, p\ 0.0001) and for post-treatment WORMS
ratings (Average Measurement ICC = 0.933, 95% CI =
0.800–0.978, F(14, 14) = 14.93, p\ 0.0001). WORMS
analysis revealed a significant worsening of osteophytes,
and bone attrition, with an improvement in synovitis
(Table 3). ICCs were calculated to ensure consistency in
the two observers’ evaluation of synovitis within the
WORMs assessment. ICCs were found to be moderately
reliable (Average Measurement ICC = 0.690, 95% CI =
0.078–0.896, F(14, 14) = 3.231, p\ 0.0001 [19]. This
facilitated the averaging of the two observer’s ratings and
revealed significant improvement in synovitis from base-
line to 1-year follow-up (t(14) = 2.39, p\ 0.05). There
were no cases of osteonecrosis.
MCID results are shown in Table 4. MCID was met by
69%, 56%, 53%, 59%, and 69% of patients at 3 months for
symptoms and stiffness, pain, daily living, sports and
recreation, and quality of life, respectively.
Mean volume of embolic injected per patient was 1.6 ml
(SD = 1.4). The mean number of genicular arteries
Table 1 Patient baseline characteristics
Age (years) median (range) 60 (45–83)
Female, n (%) 20 (53%)















NSAID non-steroidal anti-inflammatory drugs, BMI Body Mass Index,
PRP platelet-rich plasma
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VAS scores







































































Fig. 4 Boxplots depicting:
VAS scores (A), KOOS
subscale daily living (B), KOOS
subscale sports and recreation
(C), KOOS subscale pain (D),
KOOS subscale quality of life
(E), and KOOS subscale
symptoms and stiffness (F)
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embolized per patient was 1.3 (SD = 0.5). Despite tech-
nically successful GAE, two patients did not gain adequate
symptomatic improvement at follow-up and subsequently
underwent knee replacement surgery at a mean of
4 months following GAE. There were no adverse features
reported by the orthopaedic surgeons performing these
operations.
At baseline, 30 patients were taking regular analgesia
for their knee pain (paracetamol = 12, NSAIDS = 13,
opiates = 5). For the 32 patients undergoing GAE, 22 took
regular analgesia (paracetamol = 8, NSAIDS = 10, opi-
ates = 4). At 3-month follow-up, 15 patients were taking
analgesia (paracetamol = 7, NSAIDS = 5, opiates = 3).
For patients completing 1-year follow-up, 11 patients were
taking regular analgesia (paracetamol = 4, NSAIDS = 4,
Opiates = 3). No patients had any other knee-specific
treatments during follow-up, except the two that went on to
have knee arthroplasty.
27/38 (71%) of patients reported pain on injecting
contrast and embolic into the target genicular arteries.
Immediately post-embolization, these patients reported a
significant improvement in this nociceptive response on
repeat injection of contrast.
A pooled analysis of the patient satisfaction question-
naire results was performed (Table 5), defining a positive
response as a given score of 1–5, and a negative response
as 6–10 (reversed for question 7). This elucidated that 75%
Table 2 Mean Knee Injury and Osteoarthritis Outcome Scores
(KOOS) subscales
Assessment Visit Mean score p value
Daily living Baseline 52.62
6 weeks 70.59 \ 0.01
3 months 67.56 \ 0.01
12 months 59.83 0.06
Sports and recreational activities Baseline 20.16
6 weeks 39.84 \ 0.01
3 months 33.28 \ 0.01
12 months 27.19 0.03
Pain Baseline 45.46
6 weeks 66.40 \ 0.01
3 months 62.93 \ 0.01
12 months 57.47 0.02
Quality of life Baseline 21.48
6 weeks 46.98 \ 0.01
3 months 41.21 \ 0.01
12 months 36.97 \ 0.01
Symptoms and stiffness Baseline 47.21
6 weeks 66.36 \ 0.01
3 months 64.40 \ 0.01




Baseline (mean) Baseline SD 1-year mean 1-year SD p value
Cartilage 24 11.42 26.8 11.21 0.07
Marrow 4.53 4.47 5.2 4.57 0.10
Bone cysts 1 1.41 0.93 1.22 0.75
Bone attrition 1.13 1.19 1.73 1.44 0.03
Osteophytes 19.47 12.82 24.4 15.65 0.02
Menisci 2.73 2.22 2.87 2.23 0.33
Ligaments 0.13 0.35 0.13 0.35 1
Synovitis 1.73 0.88 1.13 0.51 0.01
Total 54.73 27.48 63.2 30.51 0.008
SD standard deviation
Table 4 Minimum clinically important difference (MCID) for KOOS subscale at follow-up
KOOS outcome 6 weeks 3 months 1 year
% of patients reaching MCID % of patients reaching MCID % of patients reaching MCID
Symptoms and stiffness 65 69 63
Pain 58 56 56
Daily living 65 53 50
Sports and recreational 61 59 44
Quality of life 81 69 63
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of responses were positive (p\ 0.05) about GAE as a
treatment for knee OA.
Adverse Events
All adverse events were recorded prospectively in line with
Cardiovascular and Interventional Radiological Society of
Europe (CIRSE) Quality Assurance Document and Stan-
dards for Classification of Complications [20]. Four
patients experienced mild self-limiting skin discoloration
over the embolized territory as a result of non-target
cutaneous embolization (12.5%). All cases completely
resolved within 3 weeks (Grade-3). One patient experi-
enced a small self-limiting groin haematoma (Grade 2).
From the 16 patients completing 1-year follow-up, there
were no cases of osteonecrosis of the knee joint detected on
MRI.
Discussion
Laboratory and animal experiments have identified the role
of neo-angiogenesis in the pathophysiology of knee OA,
and this has emerged as a viable embolization target.
Existing human data, including the current work, have all
reported a consistent signal that GAE is safe, technically
achievable, and beneficial in reducing pain, and functional
limitation secondary to mild to moderate knee OA at early
follow-up [8–12]. The current analysis is the largest
reported cohort with mild to moderate knee OA undergoing
GAE with a permanent embolic. Most patients experienced
an early significant improvement in pain and function at 6
weeks, which was maintained to 12 months. Bagla et al.
[10] used 75 or 100 lm permanent Embozene particles
(Boston Scientific, USA) to treat 20 patients with mild to
moderate knee OA. They report the same data trend as the
current study, with greater absolute improvement to 6
months. Differences in pain perception, disease severity,
embolic size, suspension, and delivery require further study
to elucidate the optimal patient selection and technique.
The most consistently reported adverse effect of GAE is
non-target embolization to the overlying skin [21]. The use
of cone-beam CT reveals the importance of recognizing
cutaneous branches and the need to alter microcatheter
position accordingly. Using cone-beam-CT, 100–300 lm
particles, and applying an icepack to the skin over the area
to be embolized resulted in 12% of patients experiencing
non-target cutaneous embolization. This is substantially
lower than comparable studies performing GAE with a
permanent embolic, reporting non-target cutaneous
embolization of 65% [10] and 57% [9]. Using 100–300 lm
particles, we have had no cases of non-target embolization
of the vascular supply to nerves, or bone.
WORMS analysis revealed a significant improvement in
synovitis across all patients, with no significant cartilage
loss. This finding was also reported by Okuno et al. [9], and
is aligned with the hypothesis that synovial hypervascu-
larity is an important factor in the pathological process of
knee OA, which may be exploited by GAE to reduce pain
and improve function [16, 22]. WORMS analysis also
found a significant deterioration in osteophytes and bone
attrition, not previously reported. Looking into the data,
there were four patients with significant deterioration in
osteophytes and bone attrition, with no significant differ-
ence in the remaining patients. These four patients had a
median BMI of 35, which is significantly higher than the
BMI of 25.2 for the cohort reported by Okuno et al. [9]. It
is known that high BMI is a risk factor for the progression
of knee OA [23]. The deterioration was seen throughout the
knee joint in these four patients and was not limited to the
compartments that were embolized. Despite significant
worsening of osteophytes and bone attrition, these four
patients had a mean improvement in KOOS pain from 40 at
Table 5 Patient satisfaction questionnaire outcomes on acceptability of GAE
Question Response scale Mean response (standard deviation)
1. Did you feel anxious before the procedure? 1 (no)–10 (very) 2 (3)
2. Did you feel anxious during the procedure? 1 (no)–10 (very) 3 (3)
3. Did you feel any pain during the procedure? 1 (no)–10 (very) 4 (3)
4. Was the position of lying on your back uncomfortable? 1 (no)–10 (very) 3 (3)
5. Was the length of the procedure a problem? 1 (no)–10 (very) 3 (3)
6. Did you find it difficult to stay still for the procedure? 1 (no)–10 (very) 2 (2)
7. How did the procedure compare to your expectations? 1 (worse)–10 (better) 7 (4)
8. How did you find the procedure overall? 1 (not unpleasant)–10 (very unpleasant) 3 (3)
9. Would you have the procedure again? 1 (I wouldn’t mind)–10 (I would mind) 3 (3)
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baseline to 58 at 12 months. Further investigation into the
imaging following GAE is required.
An appreciation of the anastomoses between vessels,
awareness of the embolization endpoint, and microcatheter
experience is essential in order to perform safe GAE. Ret-
rograde flow via genicular anastomoses may lead to non-
target embolization (Fig. 3). We report three cases where
there was significant retrograde flow into the popliteal artery,
resulting in a presumed risk of non-target embolization.
Whilst in other territories such as prostate artery emboliza-
tion (PAE), it is safe and effective to coil embolize vessels to
guard against non-target embolization; this practice has not
been evaluated in GAE. There are two considerations
underlying our rationale for not coiling vessels in GAE.
Firstly, we are performing the procedure in relatively young
patients (median age = 60); it is known that the genicular
arteries are essential collateral vessels in peripheral vascular
disease, and so there is a benefit in maintaining their supply
[24]. Secondly, and perhaps most importantly, the genicular
arteries provide the blood supply to the distal femur, proxi-
mal tibia, and patella. We therefore hypothesize that coil
embolization combined with particulate embolization might
disrupt the osseous blood supply, resulting in osteonecrosis.
This will not only result in a poor outcome from the GAE
procedure, but may also have a detrimental effect on future
treatments such a joint replacement surgery.
The embolization endpoint is an important aspect of safe
and effective GAE. Unlike other embolotherapies, the end-
point of GAE is not to occlude the proximal inflow vessel.
The aim is to embolize the pathological hyperaemia, whilst
maintaining the larger vascular supply to the bone (Fig. 3).
This we describe as ‘‘pruning’’, rather than blocking, and
necessitates very careful instillation of embolic.
Patient-reported outcomes from satisfaction question-
naires were supportive of GAE as an acceptable procedure
in patients with mild to moderate knee OA. Pain during the
procedure returned the highest negative mean score from
the satisfaction questionnaires. The pain experienced by
these patients was from injecting contrast/embolic at
pressure into the target genicular arteries. This was expe-
rienced by 27 patients, and was described as pain identical
to their normal arthritis pain. Interestingly, when present,
the pain desisted immediately following embolization. This
phenomenon has been reported by other authors, and
warrants further study [8, 9, 12].
The limitations of the current analysis are the small
sample size, limited follow-up period, and the lack of
experimental control group.
As with any intervention designed to benefit pain, the
placebo effect must be considered. The correct exploration
process should be translational from the laboratory,
through animal models to humans, with safety and feasi-
bility the initial priority. The complexity of measuring pain
outcome following an intervention cannot be underesti-
mated and should be a priority when designing future trials
measuring response to GAE. As a result of this interim
analysis, the GENESIS study will now follow patients to
2 years.
In conclusion, GAE of mild to moderate knee OA with a
permanent microsphere is safe, and technically achievable,
with potential efficacy at early follow-up. This work adds
to the growing evidence that GAE has the potential to
improve pain, function, and quality of life in patients with
knee OA. Further study with a control group is justified.
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